Lates News

According to the AI Flash News, Guojin Securities released a research report on April 27, giving a buy rating to Jichuan Pharmaceutical (600566.SH). The main reasons for the rating include: 1) Core varieties are under pressure due to high base or centralized procurement; 2) Product introductions are proceeding orderly, empowering long-term development; 3) Abundant cash flow, high dividend payout ratio. (Daily Economic News)